{"id":"yaz","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-10","effect":"Breakthrough bleeding"},{"rate":"5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":{"setId":"065f33e4-b587-4e66-b896-ca9ab7b7c876","title":"YAZ (DROSPIRENONE AND ETHINYL ESTRADIOL) KIT [BAYER HEALTHCARE PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The estrogen and progestin components suppress the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) surges needed for ovulation. Drospirenone, a fourth-generation progestin with antimineralocorticoid properties, also thickens cervical mucus and alters the endometrium to prevent fertilization and implantation. The antimineralocorticoid activity may help reduce water retention and bloating associated with traditional oral contraceptives.","oneSentence":"YAZ is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol (estrogen) and drospirenone (progestin), while drospirenone also provides antimineralocorticoid activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:58:20.544Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"},{"name":"Acne vulgaris (FDA-approved indication)"},{"name":"Premenstrual dysphoric disorder (PMDD)"}]},"trialDetails":[{"nctId":"NCT07181343","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)","status":"COMPLETED","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-05-28","conditions":"Psoriasis (PsO)","enrollment":18},{"nctId":"NCT05934942","phase":"PHASE1","title":"A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2023-09-08","conditions":"Healthy","enrollment":29},{"nctId":"NCT01277211","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09-19","conditions":"Contraception","enrollment":983},{"nctId":"NCT06233071","phase":"PHASE1","title":"Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®","status":"RECRUITING","sponsor":"Bio-innova Co., Ltd","startDate":"2024-02-13","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT06233058","phase":"PHASE1","title":"Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-03-05","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT03091595","phase":"PHASE2","title":"E4/DRSP Ovarian Function Inhibition Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2017-02-07","conditions":"Prevention of Pregnancy","enrollment":82},{"nctId":"NCT03126773","phase":"","title":"A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-05-02","conditions":"Menopause","enrollment":1570},{"nctId":"NCT01805817","phase":"PHASE4","title":"Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality","status":"WITHDRAWN","sponsor":"Istanbul Training and Research Hospital","startDate":"2012-12","conditions":"Contraceptive Methods Comparison","enrollment":""},{"nctId":"NCT02710708","phase":"PHASE4","title":"YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-27","conditions":"Contraception","enrollment":1921},{"nctId":"NCT01254292","phase":"PHASE3","title":"LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-06","conditions":"Contraception","enrollment":567},{"nctId":"NCT01557023","phase":"PHASE3","title":"Clinical Trial With Combination of Dienogest/Ethytnilestradiol and Drosperidona/Ethyniestradiol","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2013-07-01","conditions":"Metrorrhagia","enrollment":""},{"nctId":"NCT02885454","phase":"PHASE1","title":"To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT02488538","phase":"PHASE3","title":"Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-07","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT02562053","phase":"PHASE3","title":"Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome?","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-10","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT01608698","phase":"PHASE4","title":"Comparison of Body Weight Change During Contraception With Belara and Yasmin","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2012-06","conditions":"Body Weight Changes","enrollment":100},{"nctId":"NCT00356447","phase":"PHASE3","title":"Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-05","conditions":"Vasomotor Symptoms","enrollment":249},{"nctId":"NCT01253174","phase":"PHASE1","title":"Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-08","conditions":"Contraception","enrollment":48},{"nctId":"NCT01319500","phase":"","title":"Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2009-02","conditions":"Contraception","enrollment":3776},{"nctId":"NCT01590849","phase":"PHASE3","title":"Assessment of Autonomic Tone in Normotensive Women Using Combined Hormonal Oral Contraceptive Containing Drospirenone","status":"UNKNOWN","sponsor":"Instituto do Coracao","startDate":"2011-01","conditions":"Contraceptive Affecting the Autonomic Nervous System, Contraceptive Affecting Blood Pressure","enrollment":69},{"nctId":"NCT00905684","phase":"","title":"Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-06","conditions":"Contraception","enrollment":5446},{"nctId":"NCT01182207","phase":"PHASE1","title":"Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-07","conditions":"Healthy","enrollment":33},{"nctId":"NCT01182194","phase":"PHASE1","title":"Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-06","conditions":"Healthy","enrollment":32},{"nctId":"NCT00185419","phase":"PHASE3","title":"A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-11","conditions":"Contraception","enrollment":842},{"nctId":"NCT00185328","phase":"PHASE4","title":"Efficacy and Tolerability of Angeliq in Thai Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-09","conditions":"Postmenopause","enrollment":55},{"nctId":"NCT00623116","phase":"NA","title":"A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland","status":"UNKNOWN","sponsor":"Hospital for Children and Adolescents, Finland","startDate":"2007-12","conditions":"Kallmann Syndrome","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Drospirenone/Ethinyl Estradiol (generic name)","3mg drospirenone/ 0.02mg ethinyl estradiol"],"phase":"marketed","status":"active","brandName":"YAZ®","genericName":"YAZ®","companyName":"Teva Pharmaceuticals USA","companyId":"teva-pharmaceuticals-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YAZ is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol (estrogen) and drospirenone (progestin), while drospirenone also provides antimineralocorticoid activity. Used for Contraception, Acne vulgaris (FDA-approved indication), Premenstrual dysphoric disorder (PMDD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}